MAPK3 and cancer: Adaptive crosstalk between the RAS‐MAPK and the p38 pathway has previously been suggested [33, 34, 35], and the MEK‐ERK1/2 pathway has been shown to be activated upon p38 inhibition, which promoted cancer cell survival.